cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2004; 43:1494-1499, doi:10.1016/j.jacc.2004.02.034
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaita, F.
Right arrow Articles by Wolpert, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaita, F.
Right arrow Articles by Wolpert, C.

EXPRESS PUBLICATION

Short QT syndrome: pharmacological treatment

Fiorenzo Gaita, MD*,*, Carla Giustetto, MD*, Francesca Bianchi, MD*, Rainer Schimpf, MD{dagger}, Michel Haissaguerre, MD{ddagger}, Leonardo Calò, MD§, Ramon Brugada, MD||, Charles Antzelevitch, PhD, Martin Borggrefe, MD{dagger} and Christian Wolpert, MD{dagger}

* Division of Cardiology, Ospedale Civile di Asti, Asti, Italy
{dagger} Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
{ddagger} Division of Cardiology, Haut-Leveque, Bordeaux-Pessac, France
§ Department of Cardiac Diseases, San Filippo Neri Hospital, Rome, Italy
|| Molecular Genetics, Masonic Medical Research Laboratory, Utica, New York, USA
Experimental Cardiology Programs, Masonic Medical Research Laboratory, Utica, New York, USA

Manuscript received December 17, 2003; revised manuscript received February 11, 2004, accepted February 17, 2004.

* Reprint requests and correspondence: Dr. Fiorenzo Gaita, Division of Cardiology, Ospedale Civile di Asti, Via Botallo, 2, Asti, Italy.
gaitaf{at}libero.it

OBJECTIVES: The purpose of this study was to evaluate the efficacy of various antiarrhythmic drugs at prolonging the QT interval into the normal range and preventing ventricular arrhythmias in patients with short QT syndrome.

BACKGROUND: Short QT syndrome is a recently described genetic disease characterized by short QT interval, high risk of sudden death, atrial fibrillation, and short refractory periods.

METHODS: Six patients with short QT syndrome, five of whom had received an implantable cardioverter-defibrillator (ICD) and one child, were tested with different antiarrhythmic drugs, including flecainide, sotalol, ibutilide, and hydroquinidine, to determine whether they could prolong the QT interval into the normal range and thus prevent symptoms and arrhythmia recurrences.

RESULTS: Class IC and III antiarrhythmic drugs did not produce a significant QT interval prolongation. Only hydroquinidine administration caused a QT prolongation, which increased from 263 ± 12 ms to 362 ± 25 ms (calculated QT from 290 ± 13 ms to 405 ± 26 ms). Ventricular programmed stimulation showed prolongation of ventricular effective refractory period to ≥200 ms, and ventricular fibrillation was no longer induced.

CONCLUSIONS: The ability of quinidine to prolong the QT interval has the potential to be an effective therapy for short QT patients. This is particularly important because these patients are at risk of sudden death from birth, and ICD implant is not feasible in very young children.

Abbreviations and Acronyms
  b.i.d. = twice a day
  ECG = electrocardiographic/electrocardiography/ electrocardiogram
  ERP = effective refractory period
  ICa = slow inward Ca current
  ICD = implantable cardioverter-defibrillator
  IKr = rapid component of the delayed rectifier potassium current
  IKs = slow component of the delayed rectifier potassium current
  INa = inward sodium current
  Ito = transient outward potassium current
  IV = intravenously
  QTc = calculated QT
  QTp = predicted QT
  t.i.d. = three times a day




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. J. Perrin, P. W. Kuchel, T. J. Campbell, and J. I. Vandenberg
Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-a-go-go-Related Gene Channels
Mol. Pharmacol., November 1, 2008; 74(5): 1443 - 1452.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. A. Fozzard
Increased Sensitivity to Local Anesthetic Drugs: Bedside to Bench
Circ. Res., August 15, 2008; 103(4): 325 - 327.
[Full Text] [PDF]


Home page
EuropaceHome page
S. Viskin, C. Antzelevitch, M. F. Marquez, and B. Belhassen
Quinidine: a valuable medication joins the list of 'endangered species'
Europace, December 1, 2007; 9(12): 1105 - 1106.
[Full Text] [PDF]


Home page
CirculationHome page
S. E. Lehnart, M. J. Ackerman, D. W. Benson Jr, R. Brugada, C. E. Clancy, J. K. Donahue, A. L. George Jr, A. O. Grant, S. C. Groft, C. T. January, et al.
Inherited Arrhythmias: A National Heart, Lung, and Blood Institute and Office of Rare Diseases Workshop Consensus Report About the Diagnosis, Phenotyping, Molecular Mechanisms, and Therapeutic Approaches for Primary Cardiomyopathies of Gene Mutations Affecting Ion Channel Function
Circulation, November 13, 2007; 116(20): 2325 - 2345.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. A. Stephenson and C. I. Berul
Electrophysiological Interventions for Inherited Arrhythmia Syndromes
Circulation, August 28, 2007; 116(9): 1062 - 1080.
[Full Text] [PDF]


Home page
ChestHome page
M. G. Reinig and T. R. Engel
The Shortage of Short QT Intervals
Chest, July 1, 2007; 132(1): 246 - 249.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Antzelevitch, G. D. Pollevick, J. M. Cordeiro, O. Casis, M. C. Sanguinetti, Y. Aizawa, A. Guerchicoff, R. Pfeiffer, A. Oliva, B. Wollnik, et al.
Loss-of-Function Mutations in the Cardiac Calcium Channel Underlie a New Clinical Entity Characterized by ST-Segment Elevation, Short QT Intervals, and Sudden Cardiac Death
Circulation, January 30, 2007; 115(4): 442 - 449.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. Boriani, M. Biffi, C. Valzania, G. Bronzetti, and C. Martignani
Short QT syndrome and arrhythmogenic cardiac diseases in the young: the challenge of implantable cardioverter-defibrillator therapy for children
Eur. Heart J., October 2, 2006; 27(20): 2382 - 2384.
[Full Text] [PDF]


Home page
CMAJHome page
R. Brugada, K. Hong, J. M. Cordeiro, and R. Dumaine
Short QT syndrome
Can. Med. Assoc. J., November 22, 2005; 173(11): 1349 - 1354.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Schimpf, C. Wolpert, F. Gaita, C. Giustetto, and M. Borggrefe
Short QT syndrome
Cardiovasc Res, August 15, 2005; 67(3): 357 - 366.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. G. Priori, S. V. Pandit, I. Rivolta, O. Berenfeld, E. Ronchetti, A. Dhamoon, C. Napolitano, J. Anumonwo, M. R. di Barletta, S. Gudapakkam, et al.
A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene
Circ. Res., April 15, 2005; 96(7): 800 - 807.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. M. Scheinman and E. Keung
The year in clinical electrophysiology
J. Am. Coll. Cardiol., March 1, 2005; 45(5): 790 - 795.
[Full Text] [PDF]


Home page
EuropaceHome page
D. L. Weiss, G. Seemann, F. B. Sachse, and O. Dössel
Modelling of short QT syndrome in a heterogeneous model of the human ventricular wall
Europace, January 1, 2005; 7(s2): S105 - S117.
[Abstract] [Full Text] [PDF]



 
  cardiology careers collections past issues search home